Introduction {#S1}
============

With the development of recombinant deoxyribonucleic acid (DNA) technology in the early 1990s, the possibility of genetically engineering oncolytic viruses to improve virotherapy became a reality ([@B1]). Capitalizing on what was known about the mechanisms for oncolytic viruses, research focused on improving the safety profile, attenuating direct tumor lysis, and modulating the immune response. Beyond its potential therapeutic benefits, genetic engineering has generated new ways of monitoring and predicting sensitivity or resistance to oncolytic virotherapy ([@B2]). Various strategies, including animal models, cell lines, and even human *in vivo* gene expression studies, have been implemented to assess the effects of the oncolytic virus in a personalized way.

In 2015, the Food and Drug Administration approved the first oncolytic virus based on the results of a phase 3 trial for melanoma ([@B3]--[@B5]). Many other viruses are now being tested in clinical trials for various indications. This necessitates careful consideration of endpoints and creative new ways of monitoring therapeutic success.

Four main strategies for monitoring oncolytic viruses were surveyed: overall gene expression in tumor cells, gene expression of a few specific genes in the tumor cells, gene expression of specific transgenes introduced into the virus, and gene expression of certain viral genes.

Monitoring Overall Gene Expression of Tumor Cells (See Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}) {#S1-1}
---------------------------------------------------------------------------------------------------------------------

###### 

Tumor Genes.

  Reference                  Harvest time point: postinfection/other notes         Top upregulated genes                                                                                                                                                               Top downregulated genes                                                                                                                                                                                                                                        Pathways/functional groups most affected
  -------------------------- ----------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Haddad et al. ([@B12])     6 h                                                   SLC5A5, HIST2H4A, AK026847, HIST1H4E, HIST1H4B                                                                                                                                      BHLHB2, CX3CL1, G0S2, SOCS1                                                                                                                                                                                                                                    HMGB-1, interleukin (IL)-2, IL-6, IL8, Janus kinase/signal transducer and activator of transcription (JAK/STAT), interferon (IFN), and ERK 5 signaling
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                             24 h                                                  SLC5A5, AK026847, HSPA6, HIST2H4A                                                                                                                                                   IL8, ICAM1, SFRP1, CCL20, RSU1                                                                                                                                                                                                                                 P53- and Myc-induced apoptotic processes, pancreatic adenocarcinoma signaling, and phosphoinositide 3-kinase/v-ask murine thymoma vial oncogene homolog 1 (PI3/AKT) pathways
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Balogh et al. ([@B8])      12 h                                                  Rsad2, Cxcl11, 10869879, Ddx60, Ifnb, Ifih1, Ifnb2, 10720237, Isg15, Herc6, Usp18, Oasl2, Oasl, Oas1b, Gbp5, Gbp1, Mx1, Irgm, Ifit1, Ifit2, Ifit3, Ifi47, Cxcl9, TRAIL, Tnf, Atf3   Tradd, Fadd, etnk2, trpc3, p2ry12, galr2, rpa3                                                                                                                                                                                                                 Toll-like receptor signaling, RIG-I-like receptor signaling, IFN signaling, IFN effector pathways, apoptosis pathways, endoplasmic reticulum stress pathways, and cell cycle regulation
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Lee et al. ([@B15])        0, 24, 48, and 72 h                                   LEF1, PVRIG, SLFN11, LPP, CECR1, ARHGEF6, IRX3, STAMBPL1, IGFBP2, CD1D                                                                                                              CD151, AHNAK, TRIP6, LGALS1, MGST1, SRGN, CCND2, CCDC50, ITGB7, PDLIM1                                                                                                                                                                                         Phosphoprotein, mutagenesis site, regulation of programmed cell death, lysosome, regulation of apoptosis, and surface antigen
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Lacroix et al. ([@B11])    72 h                                                  EFTUD1, MMP1, PPM1F, LAMB3, TMEM200C, SIRPA, THEG, VPS18, RBM22, FOLR2, COX17, TFPI2, ACTL8                                                                                         ZIC1, FLRT3, MYC, FOXG1, MAPT, NFIA, PHLPP1, ZNF671, FZD3                                                                                                                                                                                                      Steroid biosynthesis, ether lipid metabolism, TGF-beta signaling pathway, Wnt signaling pathway, gonadotropin releasing hormone signaling pathway, and the Jak-STAT signaling pathway
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Reinboth et al. ([@B29])   Early (2 h)                                           114 human genes strongly correlating with viral genes                                                                                                                               Networks: posttranslational modification, free radical scavenging, gene expression, cell death, and cellular growth and proliferation. Molecular functions: cell cycle, cellular movement, development, growth and proliferation, and cell-to-cell signaling   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                             Intermediate/late (10 h)                              84 human (early) genes strongly correlating with viral genes (intermediate/late)                                                                                                    Cell death, cell cycle, lipid metabolism, small molecule biochemistry, and cellular development                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                             48 h                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Cell death, cellular growth and proliferation, protein synthesis and folding, infectious disease, genetic disorder, cell cycle, and deoxyribonucleic acid replication, recombination, and repair
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Kurozumi et al. ([@B6])    3 days                                                Cxcl11, Ifnγ, Cxcl9, Ccl12_predicted, Cxcl10, Ccl4, Il1b, Ccl5, Ccr6, Cxcr3                                                                                                         Spp1, Il6st                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Pfankuche et al. ([@B9])   1 day                                                 DDX60, DLA-79, CXCR7, F13A1, LOC100685890, CCR5, TRIM22, LOC100686473, GPR34, ENPEP                                                                                                 SERPINB2, TPM2, SCIN, VEGFB, THBS2, COL4A1, DMD, S100P, LOC608476, GSTA3                                                                                                                                                                                       WebGestalt (UP): immune response-activating signal transduction activation of immune response; immune response-regulating signaling pathway; positive regulation of immune response; response to other organism; regulation of immune response; positive regulation of immune system process; regulation of immune system process; immune response; immune system process DAVID (UP): activation of innate immune response; cell migration; leukocyte proliferation; positive regulation of programmed cell death; positive regulation of leukocyte activation; regulation of leukocyte proliferation; blood coagulation
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      WebGestalt (DOWN): blood vessel morphogenesis; positive regulation of cell migration; positive regulation of cell motility; cardiovascular system development; positive regulation of cellular component movement; circulatory system development; regulation of cell adhesion; positive regulation of locomotion; localization of cell; biological adhesion DAVID (DOWN): blood vessel development; protein amino acid glycosylation; organic acid metabolic process; regulation of neurological system process; regulation of transferase activity; blood coagulation; nucleobase, nucleoside and nucleotide metabolic process; antigen receptor-mediated signaling pathway; leukocyte proliferation
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Josupeit et al. ([@B14])   Most significantly expressed in susceptible cells     FAM49B, B4GALNT1, COL4A5, SLITRK4, SLC26A10, IFITM3, ASAP1, LAYN, NTRK2, ARHGEF25, CTGF, NXPH1, UGT8, NCAN, NAP1L3                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                             Most significantly expressed in resistant cells       CTHRC1, RPS4Y1, EIF1AY, DDX3Y, DPYD, PNMAL1, S100A10, TXLNG2P, TRIM38, SPP1, KDELR3, SPARCL1, MPPED2, FABP6, CCDC71L, EDNRB, TSPAN31, FAM213A                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Garcia et al. ([@B30])     0, 2, 6, 12, 18, 24, 30, 36, and 48 h postinfection   TNFAIP8                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Tanaka et al. ([@B16])     0, 6, 24, and 48 h postinfection                      SAMD9                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Kurozumi et al. ([@B17])   12 h postinfection                                    CYR61, Ang-2                                                                                                                                                                        TSP-1                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Zhang et al. ([@B7])       3 and 6 weeks (from the mouse chip microarray)        Ly6a, Plac8, Ly6c, Ccl8, Ifitm3, Ms4a4c, Clec4e, Ly6e, Tgtp, Ifit1, Rsad2, Ccl2, Ifi27, Ifi47, Ccl7, Dck, Ifit3, Irf7, Gas1, Gbp2, Cd69, Il18                                       Elavl2, Lmcd1, Arr3, Trip4, Crmp1, Hpd, Ewsr1, Ociad2, Cox15, Hmgn3, Nfia, Cables1, Rfxank, Tusc4, Cnot3, Magi1, Mrg2, Stag1, Sca2, Pdcd2, Tub, Ndrg1, Pigl                                                                                                    UP: major histocompatibility class I, chemokine receptor binding, chemokine activity, and cytokine activity; down: peptidases, proteases
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Jiang et al. ([@B22])      24 h                                                  Tumor necrosis factor                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Li et al. ([@B20])         48 h                                                                                                                                                                                                                                      MYCN                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Ma et al. ([@B19])         3 days                                                Dm-dNK                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Saito et al. ([@B10])      14, 18, and 22 h                                      CASP3, CASP7, CASP8, CASP9, CASP10, CYCS, IKK, NF-κB                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Han et al. ([@B18])        12, 24, and 48 h                                      *Staphylococcus* enterotoxin A                                                                                                                                                                                                                                                                                                                                                                                                                     

###### 

Methods.

  Reference                  Virus type                          Virus name                                                       Type of samples                                                                                                                                               Gene expression analysis                                                                                                                                 Viral analysis                                                                                          Pathway analysis
  -------------------------- ----------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ---------------------------------------------
  Haddad et al. ([@B12])     Vaccinia                            GLV-1h153                                                        Human pancreatic cancer cells                                                                                                                                 HG-U133A cDNA microarray chips                                                                                                                           Green fluorescent protein (GFP) expression                                                              Ingenuity Pathways Analysis (IPA)
  Balogh et al. ([@B8])      Newcastle disease virus             MTH-68/H                                                         Rat adrenal tumor cells                                                                                                                                       Affymetrix exon chip/microarray, quantitative reverse transcriptase PCR                                                                                                                                                                                          DAVID functional annotation-clustering tool
  Lee et al. ([@B15])        Vaccinia                            Pexa-Vec                                                         Human hematologic malignant cells                                                                                                                             Microarray                                                                                                                                               qPCR                                                                                                    DAVID functional annotation-clustering tool
  Lacroix et al. ([@B11])    Oncolytic parvovirus                H-1PV                                                            Human medulloblastoma cells                                                                                                                                   Microarrays, quantitative real-time PCR (QRT-PCR)                                                                                                        QPCR-assay, dot blot assay                                                                              KEGG pathway analysis
  Reinboth et al. ([@B29])   Vaccinia virus (VACV)               GLV-1h68                                                         Human melanoma cell lines                                                                                                                                     Microarray                                                                                                                                               Customized Affymetrix platform, GFP expression                                                          IPA software
  Kurozumi et al. ([@B6])    HSV-1                               hrR3                                                             Implanted Rat glioma cells intracranially into immune competent rats                                                                                          Quantitative real-time polymerase chain reaction-based microarrays, enzyme-linked immunosorbent assay (ELISA) for interferon-gamma expression by ELISA                                                                                                           
  Alain et al. ([@B25])      Reovirus                            Dearing strain of reovirus serotype 3                            Human glioma cells and Ras mouse embryo NIH3T3 cells                                                                                                          Northern blotting                                                                                                                                        Immunofluorescence                                                                                      
  Carey et al. ([@B13])      Vesicular stomatitis virus (VSV)                                                                     Human LNCaP and PC3 cells                                                                                                                                     Real-time reverse transcription (RT)-PCR, microarray analysis                                                                                                                                                                                                    IPA software
  Gholami et al. ([@B27])    Vaccinia                            GLV1h-153                                                        Human triple negative breast cancer cell lines                                                                                                                                                                                                                                                                         GFP expression                                                                                          
  Pfankuche et al. ([@B9])   Canine distemper virus (CDV)        DH82-Ond-pi                                                      Canine histiocytic sarcoma cell line and *in vivo* SCID mice model                                                                                            Microarrays                                                                                                                                              Immunofluorescence                                                                                      WebGestalt and DAVID
  Josupeit et al. ([@B14])   Oncolytic parvovirus                H-1PV                                                            Human NCH421k cells and the NCH421R and NCH421I subclones                                                                                                     Affymetrix human genome-U133 plus 2.0 microarray                                                                                                         Dot blot assay, immunofluorescence                                                                      
  Garcia et al. ([@B30])     CDV                                                                                                  Human mammary tumor and canine-derived adenofibrosarcoma cell lines                                                                                           Quantitative polymerase chain reaction (qPCR)                                                                                                            qPCR                                                                                                    
  Tanaka et al. ([@B16])     Inactivated Sendai virus particle   HVJ-E                                                            Human glioblastoma cell line U251MG                                                                                                                           Real-time quantitative PCR, microarrays                                                                                                                                                                                                                          
  Hirvinen et al. ([@B21])   VACV                                vvdd-tdTomato-hDAI                                               Human melanoma HS294T and human monocyte THP-1 cells                                                                                                          Whole Genome sequencing                                                                                                                                  Fluorescence                                                                                            BACA, David, and IPA analysis
  Kurozumi et al. ([@B17])   HSV-1                               hrR3                                                             Human U343, U87, U87ΔEGFR, and LN229 glioma cell lines, rat glioma D74/HveC cells, Fischer rats 8--10 weeks of age, and athymic nude mice 6--8 weeks of age   QRT-PCR                                                                                                                                                                                                                                                          
  Zhang et al. ([@B7])       VACV                                GLV-1h68                                                         Human ductal adenocarcinoma GI-101A cells were injected into 6- to 8-week-old female, nude mice                                                               GeneChip mouse genome array and human genome U133 plus 2.0 array                                                                                         GFP and fluorescence microscopy                                                                         Gene ontology (GO)
  Jiang et al. ([@B22])      Adenovirus                          SG502-TNF                                                        Human A549 lung cancer cell line and human TE-1 esophageal cancer cell line                                                                                   SYBR green I PCR                                                                                                                                         GFP and fluorescence                                                                                    
  Li et al. ([@B20])         Adenovirus                          ZD55-shMYCN                                                      LA1-55N human neuroblastoma cell line                                                                                                                         QRT-PCR                                                                                                                                                                                                                                                          
  Ma et al. ([@B19])         Adenovirus                          ZD55-Dm-dNK                                                      HCT-116 and SW620 Human colorectal cancer cell lines                                                                                                          RT-PCR and enzyme assay                                                                                                                                  Western blot analysis                                                                                   
  Saito et al. ([@B10])      Sindbis virus                       SIN AR399                                                        HSC-3 and HSC-4 human oral squamous cell carcinoma cell lines                                                                                                 Real-time quantitative RT-PCR                                                                                                                            Viral titers, immunoblot analysis                                                                       
  Han et al. ([@B18])        Adenovirus                          PPE3-SEA                                                         MB49 mouse bladder cancer cells                                                                                                                               RT-PCR                                                                                                                                                   Western blot analysis                                                                                   
  Sato et al. ([@B26])       Adenovirus                          OBP-301 and OBP-401                                              Acc2 and AccM human salivary gland adenoid cystic carcinoma cell lines                                                                                        Quantitative real-time RT-PCR analysis (viral gene)                                                                                                      GFP and fluorescence                                                                                    
  Guse et al. ([@B24])       Adenovirus                          Ad5/3-Δ24, Ad5-Δ24pK7, Ad5-Δ24RGD, Ad5-Δ24E3, Ad300wt, Ad5LacZ   HEY human ovarian cancer cells, 786-O human renal cancer cells, and 4- to 5-week-old female nude mice                                                                                                                                                                                                                  Real-time quantitative PCR was done with a SYBR green assay using a RotorGene system and fluorescence   
  Shin et al. ([@B23])       VSV                                 rVSV-IL12, rVSV-F                                                SCC 09 and FaDu human squamous cell carcinoma cell lines, and SCC VII murine squamous cell carcinoma cell line, and 6-week-old female C3H/HeJ mice            Real-time reverse transcriptase-polymerase chain reaction assays                                                                                                                                                                                                 

###### 

Gene Overlap.

  Upregulated genes   Reference                                                      Gene overlap by papers                                                                                                 
  ------------------- -------------------------------------------------------------- ------------------------ ----------------------------------------------- ------ -------------------------------------- -------------------------
  Rsad2               Balogh et al. ([@B8]), Zhang et al. ([@B7])                    MYC/MYCN                 Lacroix et al. ([@B11])/Li et al. ([@B20])      SPP1   Josupeit et al. ([@B14])---resistant   Kurozumi et al. ([@B6])
  Cxcl11              Balogh et al. ([@B8]), Kurozumi et al. ([@B6])                 NFIA                     Lacroix et al. ([@B11]), Zhang et al. ([@B7])                                                 
  Ddx60               Balogh et al. ([@B8]), Pfankuche et al. ([@B9])                                                                                                                                       
  Ifit1               Balogh et al. ([@B8]), Zhang et al. ([@B7])                                                                                                                                           
  Ifit3               Balogh et al. ([@B8]), Zhang et al. ([@B7])                                                                                                                                           
  Ifi47               Balogh et al. ([@B8]), Zhang et al. ([@B7])                                                                                                                                           
  Cxcl9               Balogh et al. ([@B8]), Kurozumi et al. ([@B6])                                                                                                                                        
  TNF                 Balogh et al. ([@B8]), Jiang et al. ([@B22])                                                                                                                                          
  IFITM3              Josupeit et al. ([@B14])---susceptible, Zhang et al. ([@B7])                                                                                                                          

The first method of assessing the impact of oncolytic virotherapy involves monitoring overall gene expression of tumor cells before and after virotherapy. To identify genes whose expression was altered in tumor cells during infection with an oncolytic virus, genome-wide expression profiling needs to be performed. The studies surveyed included both animal studies and studies performed on human cell lines. Kurozumi et al. used a rat intracranial glioma model in immune competent rats ([@B6]). They introduced a type one herpes simplex virus (HSV-1) and used quantitative real-time polymerase chain reaction (PCR)-based microarrays to monitor tumor gene expression. They found that oncolytic virus treatment induced at least a twofold increase or decrease in the expression of 50 genes when compared with the control. More specifically, they found numerous genes were upregulated from the chemokine family (see Table [1](#T1){ref-type="table"}). Unfortunately, Kurozumi et al. did not analyze gene clusters for these genes. Similarly, Zhang et al. also looked at tumor gene expression using an animal model. In this case, they used nude mice injected with metastatic human breast adenocarcinoma GI-101A cells ([@B7]). They monitored tumor gene expression after treatment with a vaccinia virus (VACV) using a mouse genome array and a human genome array. They found 681 genes differentially expressed when compared with controls. As opposed to the Kurozumi group, Zhang et al. used gene ontology to evaluate clustering and found upregulated genes related to the immune system, and downregulated genes related to enzymatic function (see Table [1](#T1){ref-type="table"}).

However, some reservations must be expressed regarding the use of Affymetrix mouse arrays. Since they are relatively species specific, genes that are identified as differentially expressed may primarily represent host cells infiltrating the tumor. When assessing the changes of potential cross hybridization of human genes to the mouse chip, less than 50% of the genes identified with the mouse arrays were differentially expressed according to the human chip. Furthermore, the immune-related genes that were differentially expressed displayed very low fluorescence intensities in human as compared with very high intensities displayed by the same genes in the mouse array. This would suggest that perhaps comparisons of gene expression between species should be evaluated with caution.

Balogh et al. used a rat adrenal tumor cell line, namely, pheochromocytoma cells, as the model, and looked at gene expression after infection with a recombinant oncolytic viral strain of Newcastle disease virus called MTH-68/H ([@B8]). They used a rat specific microarray chip to monitor gene expression and confirmed changes *via* quantitative reverse transcriptase PCR. They found that 729 genes were upregulated and 612 genes were downregulated with oncolytic viral treatment compared with controls. Balogh et al. relied on DAVID functional annotation-clustering tool to group the genes according to function. This clustering tool was far more elaborate than the method used by Zhang. They found pathways including receptor signaling, apoptosis, and cellular stress to be involved (see Table [1](#T1){ref-type="table"}). The detailed report they provided was extremely helpful in beginning to understand the mechanisms involved in oncolytic viral therapy. In addition, Pfankuche et al. used a canine sarcoma cell line as the tumor model and injected a canine distemper virus (CDV) called DH82-Ond-pi ([@B9]). They visualized the cells using immunofluorescence and used a canine specific microarray chip to evaluate tumor gene expression. They identified 892 upregulated genes and 869 downregulated genes when compared with controls. They analyzed these results using WebGestalt and DAVID and found that upregulated genes were primarily related to immune processes, cell migration, apoptosis, and blood coagulation (see Table [1](#T1){ref-type="table"}). Certainly, the role of oncolytic viruses in impairing angiogenesis demands further attention based on the mechanism related clues provided by this gene expression study.

Beyond the studies looking at animal cell lines, there are a few studies that looked at tumor gene expression in human cell lines. Saito et al. used two human oral squamous cell carcinoma cell lines called tHSC-4 and HSC-3 and injected the Sindbis SIN AR399 oncolytic virus ([@B10]). Using real-time quantitative reverse transcription (RT)-PCR to monitor the tumor gene expression after treatment with the virus, they found that Caspases 7, 8, and 10 were upregulated in both HSC-3 and HSC-4 cells, but that Caspases 3 and 9, cytochrome *c*, NF-κB, and IKK were only upregulated in HSC-3 cells. The likely interpretation of these data is that SIN induced oncolysis in HASC-3 cells by activating a few apoptotic pathways. Similarly, Lacroix et al. looked at six human medulloblastoma cell lines (MB) and how they are affected by treatment with the oncolytic parvovirus H-1 (H-1PV) ([@B11]). They used microarray and quantitative real-time PCR (QRT-PCR) to evaluate gene expression after oncolytic virus treatment. They focused on the 25 most significantly upregulated and the 25 most significantly downregulated genes. They used KEGG pathway analysis to identify clusters of genes and found that five pathways were particularly impacted by H-1PV infection. These included the pathways for steroid biosynthesis, ether lipid metabolism, TGF-beta signaling, Wnt signaling, gonadotropin releasing hormone signaling, and Jak-STAT signaling. One advantage in the methodology employed by the Lacroix group was focusing on the top 25. As opposed to the other groups that tried to find patterns from all the up and downregulated genes, Lacroix et al. potentially eliminated noise and were able to better identify the most important pathways. Finally, Haddad et al. looked at the PANC-1 human pancreatic cancer cell line infected with GLV-1h153, an oncolytic VACV ([@B12]). They used cDNA microarray chips to monitor gene expression after infection with the virus and used a cutoff of a twofold change to identify the most relevant genes. At 6 h postinfection, they found that 139 genes were up- or downregulated, but by 24 h after infection 5,698 genes were dysregulated. They analyzed the pathways using the Ingenuity Pathways Analysis (IPA) software and found that downregulated genes clustered around pathways associated with cell death, cell cycle, and DNA repair. Upregulated genes were associated with mechanisms related to infection. In contrast to the groups surveyed so far, Haddad et al. also labeled the virus with green fluorescent protein (GFP) and used this to determine if GFP-marker gene expression can be correlated with viral copy number. Analyzing GFP expression levels in the cells infected by the virus was shown to be both time and multiplicity of infection dependent. Considering that by 24 h postinfection almost 70% of live cells expressed GFP, and that the amount of dysregulated genes was significantly higher by 24 h, it seems reasonable to assume that the virus significantly affected the tumor. The pathway analysis enabled Haddad et al. to go a step further and begin to understand the method by which the viruses affect the tumor cells. More robust examples of combined testing of both tumor gene expression and viral levels will be reviewed in a later section.

The human studies reviewed until this point compared between tumor cells and normal cells. A slightly different methodology was employed in a few studies in which gene expression was compared between susceptible and resistant cancer cells. For example, Carey et al. capitalized on the fact that vesicular stomatitis virus (VSV) replicates selectively in cancer cells that have defects in the interferon (IFN)-I pathway ([@B13]). They looked at two different lines of prostate cancer cells. The first, human LNCaP cells, possess a defective IFN-I response, making them sensitive to VSV infection. The second, human PC3 prostate cancer cells, on the other hand, have functional IFN-I signaling, making them resistant to VSV infection. They employed real-time RT-PCR analysis and found that primary transcription, secondary transcription, and viral protein synthesis were delayed in PC3 cells compared with LNCaP cells. To look at gene expression, they used microarray and found that PC3 cells expressed many antiviral gene products compared with LNCaP cells. Furthermore, they looked at 80 different signaling pathways using IPA software and found specific pathways to be associated with a difference in gene expression between the two cell lines. Predictably, the IFN pathway had the highest percentage of differentially expressed genes. This research suggests the possibility of sensitivity markers for VSV treatment and hints at the mechanism of action of the virus. Similarly, Josupeit et al. looked at human NCH421k glioblastoma multiforme cells, which are susceptible to infection by parvovirus H-1 (H-1PV) and compared its response to H-1PV with NCH421R cells, which are a subclone resistant to H-1PV ([@B14]). They used "stem like" cell lines in NOD/SCID mice. They found a decrease in metabolic activity in the sensitive cell line compared with the resistant cell line when treated with H-1PV. When they analyzed gene expression using the Affymetrix Human Genome-U133 plus 2.0 microarray, they found 201 genes that were differentially expressed by at least threefold. They used unsupervised clustering to group the differentially expressed genes into three different categories. Some of these gene products are involved in regulating the antiviral immune response. A further example of comparing the response to oncolytic viruses in susceptible and non-susceptible cell lines is the study done by Lee et al. They compared the response of sensitive human myeloid leukemia lines and resistant human lymphoid leukemia cell lines to Pexa-Vec, a VACV engineered to express human granulocyte-macrophage colony-stimulating factor and β-galactosidase ([@B15]). Using quantitative PCR (qPCR) they found that 660 genes were upregulated at least twofold and 776 genes were downregulated at least twofold in the lymphoid cancer cell lines. In the case of the upregulated genes, changes were particularly remarkable, with more than 50 genes induced fivefold or higher, and 150 genes that were expressed three or fourfold higher, than the control. They used the DAVID functional annotation-clustering tool to classify the genes into 319 functional gene clusters. Some of the clusters included genes related to: viral replication and regulation of apoptosis.

Gene Expression of Specific Genes in the Tumor Cells {#S1-2}
----------------------------------------------------

A second strategy currently employed to monitor the efficacy of oncolytic virotherapy is to monitor the expression of specific genes in the tumor cells. Interestingly, to the best of our knowledge, no such human studies have been published. However, a number of human cell-line studies have been done. For example, Tanaka et al. focused on the sterile alpha motif containing domain (SAMD9) gene in the human glioblastoma cell line called U251MG ([@B16]). They treated this line with Sendai virus particle (HVJ-E). Using real-time quantitative PCR and microarray analysis they found that SAMD9 gene was upregulated in tumor cells treated with the virus and the SAMD9 messenger ribonucleic acid (mRNA) was upregulated in a time and dose-dependent manner. In a study by Kurozumi et al., they also looked at a limited number of genes in the tumor cells, but they looked at both human and animal cell lines ([@B17]). They looked at 10 genes in glioma cell lines following treatment with HSV-1 virus hrR3 and compared the response to controls. When they used QRT-PCR, they found that three genes in particular were dysregulated. The first, the antiangiogenic factor *TSP-1* was downregulated, and the other two, angiogenic factors *CYR61* and *Ang-2* were significantly upregulated when compared with controls. The advantage of this study over the previous one is that they were able to correlate the upregulation of CYR61 gene expression with the presence of the virus in the tumor tissue *in vivo*. CYR61 is a known protein that is involved in apoptosis, angiogenesis, the cell cycle, and extracellular matrix formation. By focusing on known genes but looking at the tumor cell expression in response to viral therapy and looking at the presence of the virus, researchers are able to better pinpoint the mechanisms at work when a virus infects a tumor cell.

Monitoring Transgene Expression {#S1-3}
-------------------------------

A third and particularly innovative strategy currently employed to monitor the efficacy of oncolytic virotherapy is the introduction of transgenes into the oncolytic virus and then analyzing gene expression of the transgene specifically. As we saw with the specific gene studies, there were no known published human studies. However, we will analyze one animal line study and a number of studies looking at human cell lines. Han et al. developed an oncolytic adenovirus PPE3-SEA that expressed the superantigen *Staphylococcus* enterotoxin A (SEA) and that has improved tumor specificity due to regulating the expression of E1A and E1B genes ([@B18]). They tested the PPE3-SEA virus against MB49 mouse bladder cancer cells *in vitro* and *in vivo*. They found that the mice treated with the virus had a significantly lower mean tumor volume than the control group. This seemed to correlate well with the increased expression of the virus mRNA *in vitro*.

In the human cell line studies, for example, Ma et al. constructed an adenoviral vector ZD55-Dm-dNK, containing the *Drosophila melanogaster* multisubstrate deoxyribonucleoside kinase---an important suicide gene ([@B19]). They looked at the expression of Dm-dNK human in colorectal cancer cells (HCT-116 and SW620) using RT-PCR. They found higher expression of the virus in the colorectal cancer cell lines, and lower levels of expression in the normal cell controls.

Similarly, Li et al. constructed ZD55-shMYCN, an oncolytic adenovirus ZD55 targeting the MYCN gene ([@B20]). They treated a p53-null and MYCN amplified human neuroblastoma cell line LA1-55N with the new virus. Using a two-step real-time reverse transcription (RT)-PCR procedure, they found that the virus selectively replicated and significantly downregulated the MYCN expression and that it was capable of effectively silencing the MYCN gene and inducing apoptosis in the tumor cells. Furthermore, they were able to demonstrate that the virus inhibited the growth of xenograft tumor *in vivo*.

In addition, Hirvinen et al. developed an oncolytic VACV that expressed intracellular pattern recognition receptor DNA-dependent activator of IFN− regulatory factors (DAI) to stimulate the innate immune system and to activate adaptive immune cells in the tumor ([@B21]). They tested this virus on two different human cell lines: human melanoma cells (HS294T) and human monocyte cells (THP-1). They used the BACA representing tools *via* the DAVID database to analyze the genes. They found that in the THP-1 cell line, there were a lot more upregulated genes than in the melanoma cell line. They used IPA and found that the most upregulated networks involved pathways connected to the activation of the immune system. More specifically, pathways related to dendritic cell growth, communication between innate and adaptive immune systems, and recognition of viruses were dysregulated. Significantly, they also found a sevenfold upregulation of *DAI* in both cell lines.

Finally, Jiang et al. developed a recombinant adenovirus using SG502 and tumor necrosis factor (TNF), yielding SG502-TNF ([@B22]). They looked at the effect of the virus on two different human cell lines: human A549 lung cancer cell line and human TE-1 esophageal cancer cell line. With the help of SYBR green I PCR, they found that the expression of TNF protein increased in both cell lines after infection with the virus. Furthermore, they found that the virus attacked the tumor cells specifically, and that they regulated the apoptotic-signaling pathway.

Shin et al. investigated human squamous cell carcinoma cell lines, murine squamous cell carcinoma cell lines, as well as a murine model ([@B23]). They used a VSV that was engineered to express the murine interleukin (IL) 12 gene called rVSV-IL12 and compared it to a non-cytokine carrying VSV virus called rVSV-F. They found that both viruses demonstrated similar infection efficiency. Real-time RT-PCR and enzyme-linked immunosorbent assay were used to look at viral replication and IL12 expression. They found that human squamous cell carcinoma cell lines infected with rVSV-IL12 had a high level of IL12 expression at 48 h postinfection. In the murine model, the animals treated with virus had a smaller tumor area than the control group. The mice treated with rVSV-IL12 had a much greater reduction of the tumor compared with the mice treated with rVSV-F. *In vivo* they showed that by day 30, none of the control mice survived, yet 3 animals injected with rVSV-F and 10 animals injected with rVSV-IL12, survived beyond day 30.

Monitoring Viral Gene Expression (See Table [4](#T4){ref-type="table"}) {#S1-4}
-----------------------------------------------------------------------

###### 

Viral Proteins Monitored.

  Viral proteins monitored   
  -------------------------- ------
  Alain et al. ([@B25])      S1
  Garcia et al. ([@B30])     CDVM
  Li et al. ([@B20])         E1A
  Sato et al. ([@B26])       E1A
  Guse et al. ([@B24])       E1A

In assessing the impact of oncolytic virotherapy, a fourth method is to look at the gene expression of the virus itself inside of the tumor cells over time. By marking the virus with GFP and measuring the viral gene expression over time within the tumor cells, there is a clear indicator of viral growth, followed by a decrease in viral presence in the tumor cell as the tumor cell is destroyed. This method has been demonstrated in a number of studies including: animal studies (*in vivo*), and *in vitro* studies with cell lines, but no human studies have been published to date to the best of our knowledge.

### Studies Where Human Cell Lines Implanted into Animals (*In Vivo*) {#S1-4-1}

In conducting animal studies, human cell lines are implanted into animals (*in vivo*). For example, Guse et al. used two different murine xenograft models, one for renal cancer and a second for ovarian adenocarcinoma ([@B24]). They co-injected a luciferase-encoding virus with eight different adenoviruses. In the ovarian cancer cell model, they found using PCR that the mice infected with some of the adenoviruses had an over 3 log increase in luciferase gene expression, a luminescence gene, compared with mice infected with other adenoviruses. They also found that gene copies of luciferase genes were increased in some of the models and decreased in others. In the renal cancer model, they used qPCR to monitor gene copies and found that they increased by three orders of magnitude in some of the lines but not at all in others. Bioluminescence demonstrated photoemission for all of the tumors that were treated which implies that the virus entered the tumors.

### Human and Mice Cell Line Studies (*In Vitro*) {#S1-4-2}

Shifting to *in vitro* studies, Alain et al. looked at human glioma cells, Ras-transformed mouse embryo NIH3T3 cells, reovirus resistant human glioma cells, and untransformed NIH3t3 cells ([@B25]). They infected these four cell lines with mammalian orthoreoviruses. Using Northern blotting, they found that outer capsid protein sigma-1 reovirus transcripts were found only in the Ras-transformed cell line and the susceptible cell line. However, they found that when the cells were treated with an E64 protease inhibitor it successfully blocked the virus. Treating with an infectious subviral particle enabled the virus to be detected even in the resistant cell line and even in the presence of E64. Furthermore they found that the level of active cathepsin B and L was increased in tumors.

Sato et al. looked at human salivary gland adenoid cystic carcinoma cell lines ([@B26]). They infected the cells with a telomerase-specific replication-selective adenovirus (OBP-301) and OBP-401, a genetically engineered adenovirus with the GFP gene. Using quantitative real-time RT-PCR, they found that E1A expression increased in infected cells. When using the virus with GFP, the intensity of the fluorescence increased in a dose-dependent manner. Another *in vitro* study was conducted by Gholami et al. They used the human triple negative breast cancer cell lines HCC38 and MDA-MB-468 ([@B27]). They infected the cells with a VACV GLV-1h153 that was engineered to express the human sodium iodine symporter gene. Using GFP, they found that the virus infected the cell lines in a time-dependent way that was proportional to the concentration of the virus.

### Using Marker Peptides to Monitor Viruses Instead of PCR {#S1-4-3}

Peng et al. developed oncolytic viruses that could be tracked *via* marker peptides ([@B28]). They used the Edmonston vaccine strain of measles virus (MV-Edm) to express either human carcinoembryonic antigen (CEA) or beta-human chorionic gonadotropin (βhCG). They injected MV-shCEA or MV-βhCG into two groups of transgenic mice. They compared detection of CEA in serum to RT-PCR for nucleocapsid RNA and found that serum CEA was a more sensitive method than PCR.

Combination Studies (Viral and Host Gene Expression) {#S1-5}
----------------------------------------------------

Until now we have reviewed studies that primarily looked either at tumor gene expression or viral gene expression. Perhaps the most interesting studies are the studies that combine both. Combination studies can potentially assess the correlation between the viral replication and the host response. Reinboth et al. looked at two different human melanoma cell lines (888-MEL and 1936-MEL) ([@B29]). They infected the cell lines with an attenuated VACV GLV-1h68. They used a platform called 36K to monitor human gene expression and they used a customized platform to monitor viral expression. To monitor viral expression, various markers were used including RUC-GFP, gusA, and the viral IFN-α/β-receptor-like secreted glycoprotein. The levels of the first two markers increased after infection, and the glycoprotein was expressed exclusively by GLV-1h68. To analyze the relationship between host cell transcription and viral replication, they assessed the correlation between viral and human gene expression at 2 h postinfection (early) and at 10 h postinfection (intermediate/late). At 2 h postinfection, they found 7 VACV genes and which were correlated to 114 human genes. Analysis with IPA demonstrated that these genes were related to the following pathways: apoptosis and the cell cycle, posttranslational modification, cellular growth and signaling, and other networks (Table [1](#T1){ref-type="table"}). They then assessed whether human early gene transcription was predictive of VACV intermediate/late transcription and found 84 human early genes that correlated. These genes were important in processes such as cellular development and death, and lipid metabolism amongst others. Upon looking at expression 48 h after infection (late), there was a significant change in the expression of genes related to cellular growth, cell death, protein synthesis and folding, DNA replication, and DNA repair.

Similarly, Garcia et al. used three human mammary tumor cell lines along with a cell line for adenofibrosarcoma of canine origin, and infected them with CDV ([@B30]). They were testing the sensitivity to CDV infection, cell proliferation, apoptosis, mitochondrial membrane potential and expression of tumor necrosis factor-alpha-induced protein 8 (TNFAIP8). Using qPCR they were able to quantify both TNFAIP8 gene, and the virus CDVM gene expression; they found that both TNFAIP8 and CDVM gene expression were positively correlated in all cell lines.

Critical Analysis: Advantages/Disadvantages of Four Strategies {#S2}
==============================================================

In critically assessing the advantages and limitations of each of the four strategies described earlier, various conclusions became clear. For example, when looking at overall gene expression changes of tumor cells, the advantages include that it generates the broadest view of what is happening inside the tumor cells after infection with the virus without the initial bias of inserting a gene and looking specifically at that gene. Of course, it is also provides a much wider scope which is more advantageous than looking at only one or two genes. The disadvantages of this method, on the other hand, is that they provide less specific information about specific pathways or mechanisms through which the tumor increases or decreases due to the wider lens used. In addition, this method provides no information on the viral gene expression or the correlation between the virus and the decrease in tumor size.

Upon analyzing the second method, namely, gene expression of specific genes in the tumor cells, we saw various strengths and weaknesses as well. For example, this method could potentially provide more information on the mechanism for tumor shrinkage or growth. In addition, since the method is more specific it makes it slightly easier to execute. Furthermore, once the specific genes are chosen, it enables a more in depth analysis of how these genes are important and how gene expression changes in the tumor cells after viral infection can have an impact on the cells.

On the other hand, looking at specific genes in the tumor cells might not reflect the overall tumor status since the broad picture of what is going on in the tumor cells is missing. Similar to the limitation of the first method, this method also does not provide any information on the viral gene expression or the correlation between the virus and the decrease in the tumor.

The third method of looking at transgenes is advantageous because it is a relatively simple study to do, allowing for effective monitoring of a specific transgene, and it is not "shooting in the dark" and looking for a wide variety of genes. In this way, researchers can test how effective a specific transgene performs. However, disadvantages include that it lacks the broader perspective of a study looking at overall gene expression and does not provide any indication of how the expression of genes in the tumor cells change after viral infection.

Monitoring viral gene expression is helpful in terms of providing information about how effectively the virus is infecting and replicating in the host cell, but provides no information about gene expression changes in the tumor cell or the mechanisms for tumor growth or shrinkage. Compared with analyzing marker peptides to monitor viral growth and replication, gene expression might not be as sensitive, but this requires further studies to confirm this finding.

Overall, in terms of future directions, it would seem that combination studies are the optimal method for studying gene expression changes. They potentially allow both a broad picture of gene expression changes in tumor cells, and the ability to correlate the tumor shrinkage or growth with viral replication. Furthermore, much information about the precise mechanisms for how the virus attacks the tumor cells can be culled from this type of study. As more combination studies are performed, patterns in the clusters of genes involved will become apparent enabling researchers to pinpoint exactly how various viruses attack tumors and providing fruitful ideas for developing a new generation of recombinant viruses that are more effective.
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